|
|
SMEs
go Health Newsletter |
Newsletter Volume 2, No 8 - January 2009|
In this
issue
part in FP7
Project
coordinator is |
UPCOMING EVENTS
Promotion of SMEs go Health in Denmark
 Announcement - 26 February 2009
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Danish representative for the “SMEs go Health” - Initiative from EuroCenter, the Danish Agency for Science, Technology and Innovation, has successfully promoted the project at two major events in Denmark during autumn 2008.
The theme of the workshop is “Maximising outcomes of EU funded research projects and Tools for success” . This workshop is organised by the Health Research Directorate of the European Commission.
|
The 5th call for transnational projects of the EraSME partnership is open!
The EraSME project is an EU initiative covering research and innovation programmes from 17 countries/regions and is funded by the 7th R&D EU Framework Programme under the ERA-NET scheme. The projects will be funded by the respective national funding programmes.
Funding possibilities will be offered to two project formats. In either case the consortium must involve at least two countries:
1. Smaller trans-national co-operation projects: at least two SMEs and one RTO (Research and Technology Organisation),
2. Larger consortia: at least four SMEs and two RTOs.
This call will be open to cooperation proposals in all fields of technology. Funding possibilities are given for projects from the following countries/regions: Austria, Belgium/Flanders, Czech Republic, France, Germany, Iceland, Ireland, Italy/Tuscany, the Netherlands, Slovenia, Spain/Madrid, and Sweden.
Documents and detailed information will be available on the following website:
http://www.era-sme.net/public/5th-call-for-proposals/5th-call-for-proposals
See section "Help Desk" for detailed information and relevant documents.
The closing date of the call will be March 31, 2009.
|
OTHER PROJECTS
KAPPA-Health: How to better exploit the results from EU Health research projects
A new EU-funded project called KAPPA-Health has been recently launched to assess and valorise the success of small and medium-sized biomedical companies (SMEs), which have received funds from the European Union Framework Programmes 6 and 7 for research and technological development.
The KAPPA-Health project will evaluate what makes an SME successful in terms of its participation in an FP6/FP7 EU co-funded research project and how this joint research can lead to successful applications.
Through survey and in depth interview of biomedical SMEs participating in FP6 “Life sciences, genomics and biotechnology for health” and FP7 “Health” theme, the KAPPA-Health project participants will identify the major performance factors by considering quantitative elements such as the number of out-licensing/new products on the market and taking into account longer term qualitative impacts in terms of sustainable growth of companies and establishment of winning business strategies.
Further info: www.kappa-health.org
Contact: Dr J. Viseur, Euro Top – Project Coordinator
SPOTLIGHT ON RESEARCH PROFILES
Health research excellence in the spotlight: Turkey
In our newsletters, we present key research and innovation actors in the “Health” area of European Member States, Associated Countries and Candidate Countries. In this newsletter, we are introducing several Turkish researchers and SMEs willing to participate in FP7 research projects. We invite you to learn more about the expertise of potential new partners for your FP7 projects!
TIPS & TRICKS TO TAKE PART IN FP7
Practical guide on EU funding
Central to the realization of the goals of the Lisbon Agenda is the need to promote the knowledge economy, in particular through research, technological development and innovation (RTDI).
EU support for RTDI is provided mainly through the Seventh Research Framework Programme (FP7), the Competitiveness and Innovation Framework Programme (CIP) and the Structural Funds.
When operating individually, these three funding sources already act as effective tools in support of RTDI. However, their value can be further enhanced by combining them. How can this be done?
The answer to this question is provided by the “Practical Guide to EU Funding Opportunities for Research and Innovation”. In addition to practical information on combining the different funding sources, the guide includes a description of each fund, advice for policy makers and an innovative checklist and scorecard. These allow potential beneficiaries to quickly identify exactly how they can access European funding at every stage of a project.
For further information and to download the guide, please visit: http://cordis.europa.eu/eu-funding-guide/home_en.html
Guidelines for preparing FP7 proposals and managing EU-funded research projects
Two guidelines have been developed by Eystein Kallhovde, Oslo Projektservice AS, Norway (www.prosjektservice.no), supporting project coordinators, work package leaders, project partners and beneficiaries of FP7 EU-funded research projects in terms of preparing proposals as well as regarding management procedures.
SUCCESS STORIES / QUOTES FROM CLIENTS
Success stories from researchers in FP7 on SGH website!
If you are still wondering about the feasibility and the benefits of a participation in an FP7-project, have a look at our newly published success stories!
Besides testimonies from SMEs successfully participating in projects under the Sixth Framework Programme (2002-2006), we now have the first success stories from SMEs participating in FP7 projects (2007-2013). Five SMEs provide a description of their participation and share their insights into the challenges, the experiences learned and the benefits gained from their Health-projects.
The first success story highlights the experiences from the Austrian biopharmaceutical SME “Oridis Biomed”. This is an Austrian biopharmaceutical company focused on the commercialization of its proprietary, disease-driven research platform enabling the medical validation of drug discovery approaches and biomarkers.
Biomed successfully joined the FP7 GENINCA-project, which aims to identify markers for novel therapeutic and/or preventative strategies, as well as facilitating tumor diagnosis, prognosis and monitoring. Markus Otte from ORIDIS Biomed underlines in his interview that, thanks to a good coordination effort, the proposal preparation phase and the negotiation phase were very straightforward and productive. Mr Otte expresses his satisfaction with his participation and gives some tips to SMEs and academia that would like to get involved in FP7 health-projects.
In each forthcoming newsletter we will highlight another success story, but you can already consult all of them on our website.
If you would like to give your comments on your experience in participating in FP7-projects or if you want to give a testimony yourself, do not hesitate to contact one of the project partners.
Newsletter by Euro Top.
